Recombinant adenovirus causes prolonged mobilization of macrophages in the anterior chambers of mice

Kacie J. Meyer,1 Danielle Pellack,1 Adam Hedberg-Buenz,1,2 Nicholas Pomernackas,1 Dana Soukup,1 Kai Wang,3 John H. Fingert,1 Michael G. Anderson1,2,4

1Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA; 2VA Center for the Prevention and Treatment of Visual Loss, Iowa City VA Health Care System, Iowa City, IA; 3Department of Biostatistics, University of Iowa, Iowa City, IA; 4Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA

Purpose: Ocular tissues of mice have been studied in many ways using replication-deficient species C type 5 adenovirus (Ad5) as a tool for manipulating gene expression. Whereas refinements to injection protocols and tropism have led to several advances in targeting cells of interest, there remains a relative lack of information concerning how Ad5 may influence other ocular cell types capable of confounding experimental interpretation. Here, a slit lamp is used to thoroughly photodocument the sequelae of intraocular Ad5 injections over time in mice, with attention to potentially confounding indices of inflammation.

Methods: A cohort of C57BL/6J mice was randomly split into three groups (Virus, receiving unilateral intracameral injection with 5×10^7 plaque-forming units (pfu) of a cargo-less Ad5 construct; Saline, receiving unilateral balanced salt solution injection; and Naïve, receiving no injections). From this initial experiment, a total of 52 eyes from 26 mice were photodocumented via slit lamp at four time points (baseline and 1, 3, and 10 weeks following initiation of the experiment) by an observer masked to treatments and other parameters of the experimental design. Following the last in vivo exam, tissues were collected. Based on the slit-lamp data, tissues were studied via immunostaining with the macrophage marker F4/80. Subsequently, three iterations of the original experiment were performed with otherwise identical experimental parameters testing the effect of age, intravitreal injection, and A195 buffer, adding slit-lamp photodocumentation of an additional 32 eyes from 16 mice.

Results: The masked investigator could use the sequential images from each mouse in the initial experiment to assign each mouse to its correct treatment group with near perfect fidelity. Virus-injected eyes were characterized by corneal damage indicative of intraocular injection and a prolonged mobilization of clump cells on the surface of the iris. Saline-injected eyes had only transient corneal opacities indicative of intraocular injections, and Naïve eyes remained normal. Immunostaining with F4/80 was consistent with ascribing the clump cells visualized via slit-lamp imaging as a type of macrophage. Experimental iterations using Ad5 indicate that all virus-injected eyes had the distinguishing feature of a prolonged presence of clump cells on the surface of the iris regardless of injection site. Mice receiving an intraocular injection of Ad5 at an advanced age displayed a protracted course of corneal cloudiness that prevented detailed visualization of the iris at the last time point.

Conclusions: Because the eye is often considered an “immune privileged site,” we suspect that several studies have neglected to consider that the presence of Ad5 in the eye might evoke strong reactions from the innate immune system. Ad5 injection caused a sustained mobilization of clump cells—that is, macrophages. This change is likely a consequence of either direct macrophage transduction or a secondary response to cytokines produced locally by other transduced cells. Regardless of how these cells were altered, the important implication is that the adenovirus led to long-lasting changes in the environment of the anterior chamber. Thus, these findings describe a caveat of Ad5-mediated studies involving macrophage mobilization, which we encourage groups to use as a bioassay in their experiments and consider in interpretation of their ongoing experiments using adenoviruses.

Recombinant adenoviruses have many advantages—and some notable disadvantages—for application as gene transfer vehicles [1-4]. One reason that adenoviruses were initially developed for gene transfer is that a great deal of their basic biology has long been well understood [5]. All adenoviruses are nonenveloped double-stranded DNA viruses with a linear double-stranded genome encased along with core proteins into an icosahedral capsid [6]. Adenoviruses can be classified into seven species (A–G), with multiple serotypes per subgroup [7]. In humans, adenovirus infection is typically mild, with the notable exception of immunocompromised patients, for which it can be life-threatening. To promote safety of recombinant adenoviruses used in laboratories, the E1 region of the adenoviral genome is typically deleted, rendering the virus...
replication incompetent and creating a location for insertion of transgene cassettes [8]. Recombinant adenoviruses typically have broad tropism, high efficiency of gene delivery, and ability to transduce both dividing and quiescent cell populations. Upon entry into the nucleus, adenovirus can initiate gene transcription without integrating into the host genome, circumventing problematic insertional mutagenesis. Replication-deficient species C type 5 adenovirus (Ad5) was among the first vectors of this type studied, and following the refinement of protocols for its efficient production [9,10], it has grown in popularity to become one of the most popular gene transfer tools used in research.

The ocular tissues of mice have been studied in many ways with Ad5 [11,12]. Most studies using Ad5 have desired transduction of two ocular tissues—retinal photoreceptors in the posterior segment and trabecular meshwork cells in the anterior segment. In both cases, effective transfer to these cell types is challenged by the high transduction efficiencies of neighboring tissues. For the retina, the RPE and Muller cells tend to be more readily transduced compared with photoreceptors [11], and in the case of the anterior chamber, the corneal endothelium tends to be transduced more than trabecular meshwork cells [13]. Transduction with replication-deficient adenoviruses is transient, with Ad5-driven reporter expression typically described as lasting for 2–7 weeks following intraocular injections [13-15]; this period can be extended with the use of anti-inflammatory treatments [14]. Refinements to injection protocols [16] and tropism [17,18] continue to improve apparent outcomes, although with more success for transfer to trabecular meshwork cells than for photoreceptors. Whereas the efficiency of transfer to desired cell types is important, it is equally important to consider how to prevent Ad5 from influencing unwanted cell types, especially cells of the immune system. While some progress in averting adenoviral immune responses has been made in other tissues [1], less has been studied or attempted in the eye [14].

Here, we used slit-lamp imaging to describe the consequences of intraocular Ad5 injection in healthy C57BL/6J mice that were photodocumented at four time points (baseline and 1, 3, and 10 weeks following initiation of the experiment). We were led to conduct this study in a comprehensive fashion following sporadic observations from pilot experiments indicating that Ad5-injected eyes had adverse reactions in the anterior chamber that were more common and severe than suggested by the existing literature, which has largely been based on histologic sampling. Our slit-lamp data indicate a highly predictable response involving corneal opacity, which resolved, and a prolonged mobilization of clump cells on the surface of the iris, which did not resolve up to the longest time points examined. These long-lived changes to macrophages of the anterior chamber could have a confounding influence in studies using adenoviral vectors, and we suggest that future experiments should include screening for them as part of their experimental design.

**METHODS**

**Experimental animals:** All experiments were performed at the University of Iowa, conducted in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research, and approved by the Institutional Animal Care Use and Committee of the University of Iowa. C57BL/6J mice were obtained from The Jackson Laboratory (Stock 000,664; Bar Harbor, ME) and subsequently bred and housed at the University of Iowa Research Animal Facility.

**Slit-lamp examination:** Slit-lamp examination and photodocumentation were performed by MGA (author; masked to treatment for the entire course of the study) at baseline (3 days before when some eyes received injections) and 1, 3, and 10 weeks following initiation of the experiment. Anterior chamber phenotypes were assessed in conscious mice using a slit lamp at 25X and 40X magnifications (SL-D7; Topcon, Tokyo, Japan), and photodocumented using a digital camera (D800; Nikon, Tokyo, Japan). All photographs were taken with identical slit-lamp settings and documented using identical camera settings and image processing. Following the final exam, eyes were grouped by MGA (still masked to treatment) based on common ocular phenotypes.

**Adenovirus injection:** A cargo-less Ad5 stock construct was purchased from the University of Iowa Viral Vector Core (Ad5CMVempty; Catalog #: VVC-U of Iowa-272, Iowa City, IA). The University of Iowa Viral Core purifies adenoviral vectors by standard ultracentrifugation using a double cesium chloride step gradient and dialyzes extensively against A195 formulation buffer [19].

Mice with normal slit-lamp examinations at baseline were randomly divided into sex-matched groups as follows: 1) Virus mice (n = 11) had one eye injected intracameraly with 5×10^7 pfu of Ad5CMVempty and one eye remaining naïve; 2) Saline mice (n = 11) had one eye injected intracameraly with balanced salt solution (BSS; Alcon Laboratories, Fort Worth, TX) and one eye remaining naïve; and 3) Naïve mice (n = 5) did not receive an injection in either eye but were otherwise treated identically to the other groups. Treatments were randomized between right and left eyes. One mouse from the Saline cohort died during the study. To test iterations of the original experiment, a second cohort of mice with
normal slit-lamp examinations at baseline was randomly divided into sex-matched groups as follows: 1) Virus mice (n = 4) had one eye injected intracameraly with 5×10^4 pfu of Ad5CMVempty and one eye remaining naïve, identical to “Virus mice” in the original experiment; 2) Buffer mice (n = 4) had one eye injected intracameraly with A195 Buffer provided by the University of Iowa Viral Vector Core and one eye remaining naïve; 3) Intravitreal mice (n = 4) had one eye injected intravitreally with 5×10^4 pfu of Ad5CMVempty and one eye remaining naïve; and 4) Aged mice (n = 4) had one eye injected with 5×10^4 pfu of Ad5CMVempty and one eye remaining naïve; three eyes in this group received intracameral injections, and one eye received an intravitreal injection.

For injections, mice were anesthetized with a mixture of 87.5 mg/kg ketamine (VetaKet®, AKORN, Lake Forest, IL) and 12.5 mg/kg xylazine (Anased, Lloyd Laboratories®, Shenandoah, IA). All eyes were diluted with 2% cyclopentolate eye drops (Alcon Laboratories). Upon full anesthesia, 0.5% proparacaine eye drops (Bausch & Lomb, Rochester, NY) were applied to all eyes to provide additional local anesthesia. For each eye designated to receive an intracameral injection, the cornea was first punctured using a 33G needle, and the aqueous humor was allowed to drain from the anterior chamber. Treatment was delivered as a 2.0 µl intracameral injection using a 30G needle with reentry via the initial puncture site. For each eye designated to receive an intravitreal injection, the eye was punctured slightly posterior to the limbus using a 33G needle. Treatment was delivered as a 2.0 µl intravitreal injection using a 30G needle with reentry via the initial puncture site. For recovery, all mice received artificial tear ointment in both eyes (AKORN), an injection of 1 mg/kg of Antisedan (Zoetis, Inc., Kalamazoo, MI), and exogenous warmth.

Histochemistry: Mice were euthanized by carbon dioxide inhalation followed by cervical spine dislocation. Eyes were collected and fixed in 4% paraformaldehyde in PBS (1X; 120 mM NaCl, 20 mM KCl, 10 mM NaPO_4_2-, 5 mM KPO_4_2-, pH 7.4) for 4 h at 4°C with agitation. Anterior cups were rinsed in PBS, cryoprotected in increasing concentrations of sucrose solutions in PBS (5%–30%), embedded in a mixture of two parts 30% sucrose and one part optimal cutting temperature compound (Tissue-Tek®; Sakura Finetek USA, Inc.; Torrance, CA), and cut in 7 µm sagittal cryosections using a cryostat. Cryosections underwent either histochemical or immunohistochemical staining. For the histochemical staining, slides were stained with hematoxylin and eosin (H&E) using standard methods and imaged by light microscopy (BX52 equipped with a DP72 camera; Olympus, Waltham, MA) using identical settings. For immunohistochemical staining, cryosections were blocked in 1% bovine serum albumin (BSA) in PBS, incubated with primary antibody (monoclonal rat anti-F4/80, 1:200 dilution, MCA497; BIO-RAD, Hercules, CA) for 1 h, rinsed, and incubated with secondary antibody (conjugated goat anti-rat Alexa Fluoro 546, 1:1,000 dilution, A11081; Invitrogen by Thermo Fisher Scientific, Waltham, MA) for 30 min, at room temperature in all cases. Both antibodies were diluted in antibody diluent (IHC-Tek™; IHC WORLD, LLC, Ellicott City, MD). Samples were rinsed, counterstained with 4',6-diamidino-2-phenylindole (DAPI), and imaged at 200X magnification using confocal microscopy (DM2500 SPE; Leica Microsystems, Inc., Buffalo Grove, IL) and dark field light microscopy with identical settings.

RESULTS

Cohort generation: To study the consequences of adenovirus following ocular injection, we used a slit lamp to document the anterior chamber over time following Ad5 injection into the anterior chamber. To collect baseline data, we first imaged 29 naïve C57BL/6j mice (male, n = 11; female, n = 18) at 12.5 weeks of age. Consistent with previous reports on sporadic ocular abnormalities in C57BL mouse strains [20], 2 of 58 eyes were found to be microphthalmic, leading to two mice being excluded from further study. At 13 weeks of age, the remaining mice (male, n = 11; female, n = 16) were randomly assigned to one of the three following treatment groups: Virus, Saline, or Naïve. Mice in the Virus group had one eye injected with Ad5CMVempty; the other eye remained naïve. Mice in the Saline group served as a control for ocular injection of a fluid, with one eye injected with BSS and the other eye remaining naïve. Both eyes of mice in the Naïve group remained naïve; otherwise, the mice received identical treatment to the experimental animals. In mice receiving injections, treatment was randomized between the left and right eyes.

Our initial study design was to have at least 10 mice in the Virus and Saline groups and 5 mice in the Naïve group. Furthermore, we sought to exclude any mice with obvious initial complications from the injection; we expected some attrition during aging; and we did not exclude any mice meeting the inclusion criteria, which could result in cohorts with greater than 10 mice. There were no obvious complications with the injections, and one mouse in the Saline group died early in the course of the study. Thus, the final number of mice in each group available for the masked study was as follows: Virus, n = 11; Saline, n = 10; and Naïve, n = 5.

Slit-lamp examinations: A masked investigator examined and photodocumented all eyes (n = 52) at the 1-, 3-, and 10-week time points. The entirety of this dataset (208 images
at 25X and 52 images at 40X) is available in Appendix 1, Appendix 2, Appendix 3, Appendix 4, Appendix 5, Appendix 6, Appendix 7 and Appendix 8. Following completion, the masked investigator used the four sequential image pairs from each mouse to assign mice into similar groupings based on common ocular phenotypes. Three mice could not be categorized because each had one eye that appeared to have been manipulated but exhibited severe corneal opacity that prevented imaging of any other anterior chamber structures. In these eyes, which were opaque throughout the entirety of the study, it was not possible to discern whether the mice had inadvertent damage from the injection procedures or severe reactions to the injected materials (Appendix 1, Appendix 2). The remaining mice could be grouped into one of three groups with common presentations.

Group 1 (n = 8) was characterized by one normal-appearing eye and one eye indicative of intraocular injection and inflammation (Figure 1, Appendix 3, Appendix 4). Eyes in this group had small corneal opacities at 1 week, which typically worsened (becoming larger and more opaque) through 3 weeks and resolved to various degrees by 10 weeks. Affected eyes sometimes had small lenticular opacities. Most notably, and completely unique to this group, all the affected eyes in this group had irides with focally “rough” appearing surfaces. When the iris could be observed through the cloudy cornea, rough-appearing irides were visible in some eyes at the 3-week time point and were present in all eyes at the(0,0),(997,999)

At completion, the masked observer (who was masked to treatment and the precise number of mice per group) assigned Group 1 to Virus, Group 2 to Saline, and Group 3 to Naïve. After unmasking, all eight eyes predicted to be in the Virus group were accurately assigned. There was one mismatch among the controls, in which a mouse in the Saline group was inaccurately predicted to be in the Naïve group. There is a significant association between the predicted treatment groups and the true treatment groups (p = 4.08E-9; True Group n = 8:10:5 [Virus:Saline:Naïve] versus Predicted Group n = 8:9:6 [Virus:Saline:Naïve]; Fisher’s exact test). All three of the noncategorized mice with severe corneal opacity were in the Virus group.

Appearance and immunostaining of clump cells: The most uniquely distinguishing feature between groups was the prolonged presence of clump cells on the surface of the iris (Figure 4). Clump cells are typically considered a type of macrophage [23,24]. To confirm that the cells we observed responding to Ad5 shared features of macrophages, we performed immunostaining with the macrophage marker F4/80 [26,27] (Figure 5) and H&E histochemical staining Appendix 9). Small round F4/80-positive cells on top of the iris stroma, in the same location as we observed the clump cells by slit lamp, were uniquely visible in most but not all sections of eyes from the Virus group. F4/80-positive cells were also observed in the ciliary body and deep in the irido-corneal angle of eyes from the Virus group.

Testing experimental iterations: To study the effect of commonly used iterations of experiments involving Ad5 ocular injection, we used a slit-lamp to document the anterior chamber over time of a second cohort of C57BL/6J mice. To collect baseline data, we first imaged 12 naïve C57BL/6J mice (male, n = 6; female, n = 6) at 12.5 weeks of age and 4 naïve C57BL/6J mice (male, n = 2; female, n = 2) at 23.5 weeks of age. No mice in this cohort were excluded from further study. When these groups of imaged mice had reached 13 and 24 weeks of age, respectively, the 16 mice were randomly assigned to one of four treatment groups with treatment randomized between left and right eyes as follows: Virus, Buffer, Intravitreal, or Aged. Mice in the Virus group had treatment identical to the “Virus” group in the original experiment, having one eye injected intracameraly with Ad5CMVempty and the other eye remaining naïve, and the group served as a positive control. Mice in the Buffer group had one eye injected intracameraly with
Figure 1. Slit-lamp images from a mouse in the Naïve group. Images from the left and right eyes of a single mouse at progressive ages showing normal appearance of the anterior chamber. A-B: Pretreatment images were collected in mice that were 12.5 weeks old. The cornea is clear, and the iris vessels are the main notable feature of the iris. With subsequent aging in these unmanipulated mice, the same healthy appearance is maintained at C-D: 1 week, E-F: 3 weeks, and G-H: 10 weeks following initiation of the experiment. See Figure 4A for a different view of the same eye and time point shown in panel G. Images at 25X magnification were collected by an investigator who was masked to treatment status at the time they were photographed.
Figure 2. Slit-lamp images from a mouse in the Saline group. Images from the left and right eyes of a single mouse at progressive ages show consequences of intraocular injection in the left eye and normal appearance of the anterior chamber in the right eye. 

A-B: Pretreatment images were collected in mice that were 12.5 weeks old. The left eye was subsequently injected with balanced salt solution (BSS).

C-D: At the 1-week time point, the injected left eye has a mild corneal opacity where the needle was inserted and slight lenticular opacity; the naïve right eye has a normal appearance.

E-F: At the 3-week and G-H: 10-week time points, the corneal opacity in the injected left eye becomes progressively less severe, and the lenticular opacity appears to be unchanged; meanwhile, the naïve right eye maintains a normal appearance. See Figure 4C for a different view of the same eye and time point shown in panel G. Images at 25X magnification were collected by an investigator who was masked to treatment status at the time the photographs were taken.
Figure 3. Slit-lamp images from a mouse in the Virus group. Images from the left and right eyes of a single mouse at progressive ages showing consequences replication deficient species C type 5 adenovirus (Ad5) injection in the left eye and normal appearance of the anterior chamber in the right eye. **A-B:** Pretreatment images were collected in mice that were 12.5 weeks old. The left eye subsequently received an intraocular injection of Ad5. **C-D:** At the 1-week time point, the injected left eye has several areas showing mild corneal opacity and lenticular opacity; the naïve right eye has a normal appearance. **E-F:** At the 3-week time point, the corneal opacity of the injected left eye has become significantly more severe, blocking visualization of the remainder of the anterior chamber; the uninjected right eye remains normal in appearance. **G-H:** At the 10-week time point, the corneal opacity in the injected left eye shows lessened severity, and where areas of the iris can be viewed, rough-appearing areas are present. The naïve right eye maintains a normal appearance. It should be noted that the apparent cloudiness of the cornea also depends on the reflectivity of the light source; see Figure 4E for a different view of the same eye and time point shown in panel G. Images at 25X magnification were collected by an investigator who was masked to treatment status at the time the photographs were taken.
Figure 4. High-magnification slit-lamp images showing the unique presence of clump cells in type 5 adenovirus (Ad5)-injected eyes. Images are from the same eyes shown at the 10-week time point in Figure 1, Figure 2 and Figure 3 but photographed at a higher magnification and with the mouse held at a more severe angle with respect to the light source. A digital enlargement of the same areas immediately to the left of each pupil is shown in the right-hand column. A-B: The irides of mice in the Naïve group retained a normal morphology with no visible clump cells throughout the study. The same eye is shown in Figure 1G. C-D: The irides of mice in the Saline group also maintained a normal morphology, continuing to lack visible clump cells. A lenticular opacity is also visible. The same eye is shown in Figure 2G. E-F: Unique to treated eyes of the Virus group, intraocular injection of Ad5 led to a notable accumulation of clump cells (white arrow; several additional cells are visible but unmarked) on the surface of the iris. Lenticular and corneal opacity is also apparent. The same eye is shown in Figure 3G. Images at 40X magnification were collected by an investigator who was masked to treatment status at the time the photographs were taken.
Figure 5. Localization of the macrophage marker F4/80 to clump cells in type 5 adenovirus (Ad5)-injected eyes. Fluorescent and light micrographs of eyes immunostained with F4/80 and counterstained with 4',6-diamidino-2-phenylindole (DAPI; nuclear stain) in treated eyes of mice from the Saline cohort (left column) compared with those of mice from the Virus cohort (right column). 

A-B: The central cornea shows a similar localization and prevalence of F4/80+ cells. C-F: the mid-peripheral iris and G-J: iridocorneal angle show an increased prevalence of F4/80+ cells localized along the anterior iris stroma, matching the location of clump cells visualized via slit-lamp exam (white arrowheads). Note that F4/80+ cells also appear to be pigment laden, which is an additional feature ascribed to clump cells. F4/80+ cells are also prominent in the posterior iris pigmented epithelium and iridocorneal angle of Ad5-injected eyes. Notation of the prominent intraocular structures is indicated (white text) in panel G. Scale bar = 100 µm for (A-F) and (G-J).
A195 Buffer, a common adenovirus vehicle, and the other eye remained naïve. Mice in the Intravitreal group had one eye injected intravitreally with Ad5CMVempty, while the other eye remained naïve. Finally, mice in the Aged group were 24-weeks-old and had one eye injected with Ad5CMVempty, while the other eye remained naïve; three eyes in this group received an intracameral injection, and one received an intravitreal injection.

A masked investigator examined and photodocumented all eyes (n = 32) at the 1-, 3-, and 10-week postinjection time points. The entirety of this dataset (128 images at 25X and 32 images at 40X) is available in Appendix 10, Appendix 11, Appendix 12, Appendix 13, Appendix 14, Appendix 15, Appendix 16, Appendix 17. Following completion, the masked investigator used the four sequential image pairs from each mouse to assign mice into four groupings based on common ocular phenotypes.

Group 1 (n = 4) was characterized by one normal-appearing eye and one eye indicative of intracameral injection and inflammation (Figure 6, Appendix 10, Appendix 11). Eyes in this group had small focal corneal opacities at 1 week, which typically worsened (larger and more opaque) through 3 weeks and resolved to various degrees by 10 weeks. Most notably, all the affected eyes in this group had irides with focally “rough” appearing surfaces. When the iris could be observed through the cloudy cornea, rough-appearing irides were present in all eyes at the 10-week time point. Group 2 (n = 4) was characterized by one normal-appearing eye and one eye indicative of intracameral injection (Figure 6, Appendix 12, Appendix 13). Eyes in this group had a mild focal corneal cloudiness at the 1-week time point that resolved over time and had normal appearing irides. Group 3 (n = 4) was characterized by one normal appearing eye and one eye indicative of inflammation (Figure 6, Appendix 14, Appendix 15). Eyes in this group have various degrees of diffuse corneal cloudiness. When the iris could be observed through the cloudy cornea, rough-appearing irides were present in all eyes at the 10-week time point. Group 4 (n = 4) was characterized by one normal-appearing eye and one eye indicative of intracameral injection and inflammation (Figure 6, Appendix 16, Appendix 17). Eyes in this group were characterized by corneal cloudiness to the extent that visualization of the iris was not possible at the 10-week time point. Notably, all eyes in this group (including naïve eyes) were larger than eyes in Groups 1–3.

At completion, the masked observer (who was masked to treatment and the precise number of mice per group) assigned Group 1 to Virus (positive control), Group 2 to Buffer, Group 3 to Intravitreal, and Group 4 to Aged. After unmasking, all 32 eyes were assigned to the correct group.

**DISCUSSION**

Although the ophthalmic slit lamp has long been the primary instrument used in clinical ophthalmology, its use in research with mice remains uncommon. To our knowledge, we are the first to thoroughly characterize the sequelae of Ad5 injection in the anterior chamber of mice via slit-lamp photodocumentation. The results show that injection of the Ad5 vector—empty of any gene therapy inserts—results in changes to the anterior chamber involving transient corneal opacity and a persistent change in the localization of macrophages on the surface of the iris. The timeframe of these changes suggests that they are likely to be longer lived than viral gene expression. In describing the appearance and location of these Ad5-responsive macrophages, our results establish how slit-lamp exams can be used as a bioassay for inflammatory events in ongoing research using viral vectors.

The biologic events allowing Ad5 to deliver gene therapy constructs to cells have been extensively studied. Capsid proteins typically mediate cellular internalization of Ad5 via attachment to the cell surface coxsackievirus and adenovirus receptor (CAR; in mice encoded by the Cxadr gene) [28,29], which is followed by interaction with integrins [30,31] (reviewed in [32-34]). CAR-negative cells are typically described as being poorly transduced by Ad5. However, several CAR-independent pathways mediating Ad5 transduction are also known. Ad5 can bind with multiple blood factors, such as blood coagulation factor X [35], which helps protect the adenovirus complex from attack by the classical complement pathway [36] and facilitates transduction by bridging the virus to cell surface heparin sulfate proteoglycans. In cultured cells, this mechanism mediated by sulfated glycan has a prominent role in transduction of hepatocytes, but there are conflicting data regarding its importance for transduction of the mouse liver by Ad5 in vivo [37] and a species-dependent difference in the influence of human versus mouse blood coagulation factor X proteins in transduction that complicates the interpretation of some studies [38]. In macrophages, scavenger receptor A (in mice, encoded by the Msr1 gene) is yet another Ad5 receptor [39]. The possibility of additional receptors awaiting characterization has been implicated by several studies [38,40,41]. Once bound to a receptor, Ad5 is internalized via clathrin-mediated endocytosis [42] or macropinocytosis [43]. After additional trafficking steps, the viral genome is ultimately inserted into the host nucleus [44]. The viral genome remains episomal and expresses any cargo gene transcripts until cell division has diluted the adenovirus to insignificant levels or the immune system has destroyed the transduced cells.
Figure 6. High-magnification slit-lamp images showing the results of experimental iterations for type 5 adenovirus (Ad5) intraocular injections. Images are from the same eyes shown at the 10-week time point in Appendix 10, Appendix 12, Appendix 14, and Appendix 16 but photographed at a higher magnification and with the mouse held at a more severe angle with respect to the light source. Images at 40X magnification were collected by an investigator who was masked to treatment status at the time the photographs were taken. A digital enlargement of the same areas immediately to the left of each pupil is shown in the right-hand column.  

A-B: In the Virus-positive control group, anterior chamber injection of Ad5 led to a notable accumulation of clump cells (white arrow, several additional cells visible but unmarked) on the surface of the iris, replicating the experiment shown in Figure 4E-F.  

C-D: The irides of mice in the Buffer group (anterior chamber injection of A195 buffer) maintained a normal morphology throughout the study, continuing to lack visible clump cells.  

E-F: In the Intravitreal group, an intravitreal injection of Ad5 led to a notable accumulation of clump cells (white arrow, several additional also visible but unmarked) on the surface of the iris.  

G-H: The eyes of the mice in the Aged group that received an intraocular injection of Ad5 all had corneal cloudiness at the 10-week time point that precluded visualization of the iris.
There is also a broad framework for predicting the concurrent immunologic events associated with the presence of recombinant Ad5 in a tissue. Adenoviruses elicit strong immune responses, even when they are initially injected into “immune privileged” sites in the eye. Viral antigens and transgene products are both capable of activating adaptive immune responses [45]. Consequently, intraocular injections of Ad5 are followed by intraocular presence of CD4+ and CD8+ T cells and generation of new presenting antibodies [35]. Hamilton and colleagues previously showed that repeated injections of Ad5 with an empty cassette did not interfere with subsequent expression of Ad5 with a luciferase reporter, suggesting that the immune privilege of the eye was likely protecting it from mounting an immune response against Ad5 [46]. However, since the time of Hamilton’s study, it has become increasingly clear that innate immunity also needs to be considered. Adenoviruses elicit strong innate immune responses [47,48]. In cells associated with innate immunity, such as macrophages and dendritic cells, Ad5 interacts with pathogen recognition receptors (PRRs) and stimulates the release of numerous cytokines and chemokines [49]. There are many classes of PRRs, with toll-like receptors being one of the most studied [50,51]. Many serotypes of adenovirus interact with PRRs, and the biology of these interactions has been studied with particular intensity at the ocular surface, where they are critically important to adenoviral keratoconjunctivitis [52]. Interestingly, innate responses to Ad5 may be quite broad and evoke proinflammatory responses from “nonimmune” cell types, including epithelial cells [53-55]. For example, cultured human conjunctival epithelial cells transduced with Ad5 have an upregulation of interleukin-6 (IL-6), interleukin-8 (IL-8), and intracellular adhesion molecule-1 (ICAM-1) [55].

In the specific context of intraocular Ad5 injections, relevant biologic and immunologic consequences can be predicted, but many remain untested. The Ad5 receptor(s) for tissues transduced in the anterior chamber have not been defined. Because blood coagulation factor X does not seem to be abundant in aqueous humor [56], the sulfated glycan-mediated pathway for transduction seems unlikely for Ad5 injected directly into the anterior chamber. The sustained mobilization of clump cells in our experiment could represent either a consequence of direct macrophage transduction or a secondary response to cytokines produced locally by other transduced cells. Regardless of how these cells were altered, the important implication is that the adenovirus led to long-lasting changes in the environment of the anterior chamber. Had the Ad5 we injected been carrying transgene cargo, it would not have been possible to discern whether phenotypic changes were specific to the cargo gene versus the cargo gene in the context of the now-altered environment of the anterior chamber. Could different injection techniques, concentrations, tropism, serotypes, or genetic backgrounds of mice have made a difference in our findings? These are undoubtedly relevant variables, but our findings and the existing literature indicate that cautionary interpretations are appropriate—many adenovirus-transduced cells are likely to have an altered expression of cytokines induced by PRR signaling. We suspect that multiple studies have overlooked the clump cell phenotype because they have primarily used histology as an assay, which may show few, if any, macrophages altered by Ad5 in any given section but these changes would be readily seen with the broader view from slit-lamp examination. It is also relevant that small changes in cytokines in vivo may be undetectable by biochemical assays but still physiologically important. There are some caveats relevant to our study that should be considered. First, we did not directly measure any cytokines, chemokines, or PRR signaling in Ad5-affected eyes. We suggest their presence based on the literature, and our hypothesis has not been tested. Second, we have reliably demonstrated that Ad5 injection caused a prolonged mobilization of clump cells, and we provided detailed photodocumentation of the iris that has been correlated with immunolabeling. However, much remains unknown about the nature of these cells. Visibly, the cells are identical in appearance and similar in apparent abundance to those we have previously studied in mice with various forms of iris disease [21,22]. Several studies have shown that gene expression changes driven by intraocular injection of Ad5 typically last only 2–7 weeks [13-15]. Assuming a similar time course occurred in our experiments, the prolonged mobilization of clump cells at 10 weeks following injection predicts that the iris changes caused by Ad5 injection are likely longer lived than the Ad5 itself. Third, to avoid potential complications from anesthesia or rebound tonometry, our current experiments did not collect any intraocular pressure (IOP) data, which might be relevant considering the localization of F4/80-positive cells deep in the iridocorneal angle and proximity to the aqueous humor drainage structures.

There remains much promise for viral-mediated approaches in studying anterior chamber physiology using mice [57,58]. Our current findings describe a caveat of Ad5-mediated studies involving macrophage mobilization, which we encourage groups to monitor and consider in their ongoing experiments using adenoviruses.
APPENDIX 1.
To access the data, click or select the words “Appendix 1.” Complete data set of 25X slit-lamp images from three mice at multiple ages which were not able to be categorized in the masked study because of severe corneal opacity.

APPENDIX 2.
To access the data, click or select the words “Appendix 2.” Complete data set of 40X slit-lamp images from three mice at the 10-week time point which were not able to be categorized in the masked study because of severe corneal opacity.

APPENDIX 3.
To access the data, click or select the words “Appendix 3.” Complete data set of 25X slit-lamp images from eight mice at multiple ages assigned to the Virus group in the masked study.

APPENDIX 4.
To access the data, click or select the words “Appendix 4.” Complete data set of 40X slit-lamp images from eight mice at the 10-week time point assigned to the Virus group in the masked study.

APPENDIX 5.
To access the data, click or select the words “Appendix 5.” Complete data set of 25X slit-lamp images from nine mice at multiple ages assigned to the Saline group in the masked study.

APPENDIX 6.
To access the data, click or select the words “Appendix 6.” Complete data set of 40X slit-lamp images from nine mice at the 10-week time point assigned to the Saline group in the masked study.

APPENDIX 7.
To access the data, click or select the words “Appendix 7.” Complete data set of 25X slit-lamp images from six mice at multiple ages assigned to the Naïve group in the masked study.

APPENDIX 8.
To access the data, click or select the words “Appendix 8.” Complete data set of 40X slit-lamp images from six mice at the 10-week time point assigned to the Naïve group in the masked study.

APPENDIX 9.
To access the data, click or select the words “Appendix 9.” Persistence of clump cells in the iridocorneal angle of eyes following intraocular Ad5 injection. Light micrographs collected from opposite poles (left vs. right column) of hematoxylin and eosin-stained histological sections from the same eye shown at (A–B) 200X and (C–D) 400X total magnification. Areas within inset boxes (top row) are show at higher magnification below (bottom row). Note that despite some variability, there is a persistent localization of clump cells deep within the iridocorneal angle with proximity to the drainage structures. Scale bar = 50 µm.

APPENDIX 10.
To access the data, click or select the words “Appendix 10.” Complete data set of 25X slit-lamp images from four mice at multiple ages assigned to the Virus positive group in the masked study of experimental iterations.

APPENDIX 11.
To access the data, click or select the words “Appendix 11.” Complete data set of 40X slit-lamp images from four mice at the 10-week time point assigned to the Virus positive group in the masked study of experimental iterations.

APPENDIX 12.
To access the data, click or select the words “Appendix 12.” Complete data set of 25X slit-lamp images from four mice at multiple ages assigned to the Buffer group in the masked study of experimental iterations.

APPENDIX 13.
To access the data, click or select the words “Appendix 13.” Complete data set of 40X slit-lamp images from four mice at the 10-week time point assigned to the Buffer group in the masked study of experimental iterations.

APPENDIX 14.
To access the data, click or select the words “Appendix 14.” Complete data set of 25X slit-lamp images from four mice at multiple ages assigned to the Intravitreal group in the masked study of experimental iterations.
APPENDIX 15.

To access the data, click or select the words “Appendix 15.” Complete data set of 40X slit-lamp images from four mice at the 10-week time point assigned to the Intravitreal group in the masked study of experimental iterations.

APPENDIX 16.

To access the data, click or select the words “Appendix 16.” Complete data set of 25X slit-lamp images from four mice at multiple ages assigned to the Aged group in the masked study of experimental iterations.

APPENDIX 17.

To access the data, click or select the words “Appendix 17.” Complete data set of 40X slit-lamp images from four mice at the 10-week time point assigned to the Aged group in the masked study of experimental iterations.

ACKNOWLEDGMENTS

This work was supported in part by Merit Review Award (101RX00481) from the USA Department of Veterans Affairs RR&D Service and an NIH/NEI Center Support Grant to the University of Iowa (P30EY025580). AHB was supported by Training Grant Award (T32DK112751). The contents do not represent the views of the USA Department of Veterans Affairs or the USA Government.

REFERENCES

1. Ritter T, Lehmann M, Volk HD. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 2002; 16:3-10. [PMID: 11908997].
2. Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 2013; 36:1-22. [PMID: 23435812].
3. Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene Therapy Vectors. Mol Ther 2020; 28:709-722.[PMID: 31968213].
4. Barry MA, Rubin JD, Lu SC. Retargeting adenoviruses for therapeutic applications and vaccines. FEBS Lett 2020; 12:1918-1946.[PMID: 31944286].
5. Crystal RG. Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther 2014; 25:3-11. [PMID: 24444179].
6. Mangel WF, San Martin C. Structure, function and dynamics in adenovirus maturation. Viruses 2014; 6:4536-70. [PMID: 25421887].
7. Robinson CM, Singh G, Lee JY, Dehghan S, Rajaiya J, Liu EB, Yousuf MA, Betensky RA, Jones MS, Dyer DW, Seto D, Chodosh J. Molecular evolution of human adenoviruses. Sci Rep 2013; 3:1812.[PMID: 23657240].
8. Danthine X, Imperiale MJ. Production of first generation adenovirus vectors: a review. Gene Ther 2000; 7:1707-14. [PMID: 11083491].
9. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 2000; 7:1034-8. [PMID: 10871752].
10. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharif KA, Luu HH, Haydon RC, Kinzler KW, Vogelstein B, He TC. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2007; 2:1236-47. [PMID: 17546019].
11. Bennett J, Wilson J, Sun D, Forbes B, Maguire A. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci 1994; 35:2535-42. [PMID: 8163342].
12. Mathioul B, Couton D, Perricaudet M, Briand P. In vivo adenovirus-mediated gene transfer into ocular tissues. Gene Ther 1994; 1:122-6. [PMID: 7584067].
13. Budenz DL, Bennett J, Alonso L, Maguire A. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest Ophthalmol Vis Sci 1995; 36:2211-5. [PMID: 7558714].
14. Millar JC, Pang IH, Wang WH, Wang Y, Clark AF. Effect of immunomodulation with anti-CD40L antibody on adenoviral-mediated transgene expression in mouse anterior segment. Mol Vis 2008; 14:10-9. [PMID: 18246028].
15. Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR, Wei LL. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis 2008; 14:2535-46. [PMID: 19122827].
16. Li G, Gonzalez P, Camras LI, Navarro I, Qiu J, Challta P, Stamer WD. Optimizing gene transfer to conventional outflow cells in living mouse eyes. Exp Eye Res 2013; 109:8-16. [PMID: 23337742].
17. Ueyama K, Mori K, Shoji T, Omat H, Gehlbach PL, Brough DE, Wei LL, Yoneya S. Ocular localization and transduction by adenoviral vectors targeting distinct cell types in the retina. Invest Ophthalmol Vis Sci 2010; 9:e108071-9. [PMID: 23657240].
18. Sweigard JH, Cashman SM, Kumar-Singh R. Adenovirus vectors targeting distinct cell types in the retina. Invest Ophthalmol Vis Sci 2010; 51:2219-28. [PMID: 19892875].
19. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiero DR, Chin S, Chen M, Zhu DM, Shiver JW, Volkin DB. Development of stable liquid formulations for adenovirus-based vaccines. J Pharmacol Sci 2004; 93:2458-75. [PMID: 15349956].
20. Meyer KJ, Anderson MG. Genetic modifiers as relevant biological variables of eye disorders. Hum Mol Genet 2017; 26:R1R58-R67. [PMID: 28482014].
21. Anderson MG, Libby RT, Mao M, Cosma IM, Wilson LA, Smith RS, John SW. Genetic context determines
susceptibility to intraocular pressure elevation in a mouse pigmentary glaucoma. BMC Biol 2006; 4:20.[PMID: 16827931].

22. Anderson MG, Hawes NL, Trantow CM, Chang B, John SW. Iris phenotypes and pigment dispersion caused by genes influencing pigmentation. Pigment Cell Melanoma Res 2008; 21:565-78. [PMID: 18715234].

23. Marneros AG, Olsen BR. Age-dependent iris abnormalities in collagen XVIII/endostatin deficient mice with similarities to human pigment dispersion syndrome. Invest Ophthalmol Vis Sci 2003; 44:2367-72. [PMID: 12766032].

24. Wobmann PR, Fine BS. The clump cells of Koganei. A light and electron microscopic study. Am J Ophthalmol 1972; 73:90-101. [PMID: 4621392].

25. Chinnery HR, McMenamin PG, Dando SJ. Macrophage physiology in the eye. Pflugers Arch 2017; 469:501-15. [PMID: 28233124].

26. Dos Anjos Cassado A. F4/80 as a Major Macrophage Marker: The Case of the Peritoneum and Spleen. Results Prob Cell Differ 2017; 62:161-79. [PMID: 28455709].

27. McMenamin PG, Crewe J, Morrison S, Holt PG. Immunomorphologic studies of macrophages and MHC class II-positive dendritic cells in the iris and ciliary body of the rat, mouse, and human eye. Invest Ophthalmol Vis Sci 1994; 35:3234-50. [PMID: 8045716].

28. Bergelson JM, Cunningham JA, Drogueut G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxackie B viruses and adenoviruses 2 and 5. Science 1997; 275:1320-3. [PMID: 9036860].

29. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94:3352-6. [PMID: 9096397].

30. Nakano MY, Boucke K, Suomalainen M, Sidwill RP, Greber UF. The first step of adenovirus type 2 disassembly occurs at the cell surface, independently of endocytosis and escape to the cytosol. J Virol 2000; 74:7085-95. [PMID: 10888649].

31. Wickham TJ, Mathias P, Chereshe DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73:309-19. [PMID: 8477447].

32. Stepanenko AA, Chekhonin VP. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX. Virus Res 2018; 257:40-51. [PMID: 30125593].

33. Nemerow GR, Stewart PL. Insights into Adenovirus Uncoating from Interactions with Integrins and Mediators of Host Immunity. Viruses 2016; 8:337.[PMID: 28009821].

34. Zhang Y, Bergelson JM. Adenovirus receptors. J Virol 2005; 79:12125-31. [PMID: 16160140].

35. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francischetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132:397-409. [PMID: 18267072].

36. Xu Z, Qiu Q, Tian J, Smith JS, Conenello GM, Morita T, Byrnes AP. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 2013; 19:452-7. [PMID: 23524342].

37. Zaiss AK, Foley EM, Lawrence R, Schneider LS, Hoveida H, Seerest P, Catapang AB, Yamaguchi Y, Alemany R, Shayakhmetov DM, Esko JD, Herschman HR. Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo. J Virol 2016; 90:412-20. [PMID: 26491162].

38. Zaiss AK, Lawrence R, Elashoff D, Esko JD, Herschman HR. Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate. J Biol Chem 2011; 286:24535-43. [PMID: 21596747].

39. Haisma HJ, Boesjes M, Beerens AM, van der Strate BW, Curiel DT, Pluiddemann A, Gordon S, Bellu AR. Scavenger receptor A: a new route for adenovirus 5. Mol Pharm 2009; 6:366-74. [PMID: 19227971].

40. Lopez-Gordo E, Doszpolyo A, Duffy MR, Coughlan L, Bradshaw AC, White KM, Denby L, Nicklin SA, Baker AH. Defining a Novel Role for the Coxackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vivo in the Presence of Mouse Serum. J Virol 2017; 91:e02847-16.[PMID: 28381574].

41. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001; 8:1347-53. [PMID: 11571572].

42. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004; 6:Suppl 152-63. [PMID: 14978758].

43. Xie J, Chiang L, Contreras J, Wu K, Garner JA, Medina-Kauwe L, Hamm-Alvarez SF. Novel fiber-dependent entry mechanism for adenovirus serotype 5 in lacrimal acini. J Virol 2006; 80:11833-51. [PMID: 16987972].

44. Leopold PL, Crystal RG. Intracellular trafficking of adenovirus: many means to many ends. Adv Drug Deliv Rev 2007; 59:810-21. [PMID: 17705746].

45. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3:137-44. [PMID: 8867861].

46. Hamilton MM, Brough DE, McVey D, Bruder JT, King CR, Wei LL. Repeated administration of adenovector in the eye results in efficient gene delivery. Invest Ophthalmol Vis Sci 2007; 48:299-305. [PMID: 16384977].

47. Atasheva S, Yao J, Shayakhmetov DM. Innate immunity to adenovirus: lessons from mice. FEBs Lett 2019; 593:3461-83. [PMID: 31769012].

48. Hartman ZC, Appleford DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008; 132:1-14. [PMID: 18036698].
49. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007; 81:3170-80. [PMID: 17229689].

50. Hartman ZC, Black EP, Amalfitano A. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology 2007; 358:357-72. [PMID: 17027060].

51. Hensley SE, Amalfitano A. Toll-like receptors impact on safety and efficacy of gene transfer vectors. Mol Ther 2007; 15:1417-22. [PMID: 17551505].

52. Pennington MR, Saha A, Painter DF, Gavazzi C, Ismail AM, Zhou X, Chodosh J, Rajaiya J. Disparate Entry of Adenoviruses Dictates Differential Innate Immune Responses on the Ocular Surface. Microorganisms 2019; 7:351 [PMID: 31540200].

53. Tamanini A, Nicolis E, Bonizzato A, Bezzzri V, Melotti P, Assael BM, Cabrini G. Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol 2006; 80:11241-54. [PMID: 16956941].

54. Tibbles LA, Spurrell JC, Bowen GP, Liu Q, Lam M, Zaiss AK, Robbins SM, Hollenberg MD, Wickham TJ, Muruve DA. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C–X-C chemokine IP-10. J Virol 2002; 76:1559-68. [PMID: 11799150].

55. Tsubota K, Inoue H, Ando K, Ono M, Yoshino K, Saito I. Adenovirus-mediated gene transfer to the ocular surface epithelium. Exp Eye Res 1998; 67:531-8. [PMID: 9878215].

56. Liu P, Thomson BR, Khalatyan N, Feng L, Liu X, Savas JN, Quaggin SE, Jin J. Selective permeability of mouse blood-aqueous barrier as determined by (15)N-heavy isotope tracing and mass spectrometry. Proc Natl Acad Sci USA 2018; 115:9032-7. [PMID: 30127000].

57. Dang Y, Loewen R, Parikh HA, Roy P, Loewen NA. Gene transfer to the outflow tract. Exp Eye Res 2017; 158:73-84. [PMID: 27131906].

58. Pang IH, Millar JC, Clark AF. Elevation of intraocular pressure in rodents using viral vectors targeting the trabecular meshwork. Exp Eye Res 2015; 141:33-41. [PMID: 26025608].